Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Royalty Pharma plc, 3 years.
Royalty Pharma plc
Director · CEO, Chairman of the Board
ProKidney Corp.
Director
Chief executive roles
Royalty Pharma plc
· CEO, Chairman of the Board
Dates unknown
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Royalty Pharma plc June 4, 202694.0%
-
ProKidney Corp. May 29, 202599.2%
-
Royalty Pharma plc May 12, 202595.0%
-
Royalty Pharma plc June 6, 202496.6%
-
Royalty Pharma plc June 22, 202398.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 5, 2026 | Royalty Pharma plc | Grant or award | +65,216 | — | — |
| May 6, 2026 | Royalty Pharma plc | Grant or award | +143,821 | — | — |
| Feb 11, 2026 | Royalty Pharma plc | Grant or award | +157,828 | — | — |
| Nov 5, 2025 | Royalty Pharma plc | Grant or award | +36,559 | — | — |
| Aug 6, 2025 | Royalty Pharma plc | Grant or award | +21,901 | — | — |
| Jun 3, 2025 | ProKidney Corp. | Derivative conversion | +3,823,996 | — | — |
| Jun 3, 2025 | ProKidney Corp. | Other | −3,823,996 | — | — |
| May 16, 2025 | Royalty Pharma plc | Other | +530,348 | — | — |
| May 8, 2025 | Royalty Pharma plc | Grant or award | +288,352 | — | — |
| Feb 4, 2025 | ProKidney Corp. | Derivative conversion | +532,535 | — | — |
| Feb 4, 2025 | ProKidney Corp. | Other | −532,535 | — | — |
| Jun 13, 2024 | ProKidney Corp. | Open-market purchase | +22,617,909 | $2.42 | $54,735,340 |
| Feb 5, 2024 | ProKidney Corp. | Derivative conversion | +748,952 | — | — |
| Feb 5, 2024 | ProKidney Corp. | Other | −748,952 | — | — |
| Nov 16, 2023 | Royalty Pharma plc | Other | −383,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.